(ULTA) Ulta Beauty - Overview
Sector: Consumer CyclicalIndustry: Specialty Retail | Exchange NASDAQ (USA) | Currency USD | Market Cap: 23.389m | Total Return 37.8% in 12m
Stock: Cosmetics, Fragrance, Haircare, Skincare, Tools
Total Rating 65
Risk 33
Buy Signal -0.75
| Risk 5d forecast | |
|---|---|
| Volatility | 39.2% |
| Relative Tail Risk | -17.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.94 |
| Alpha | 21.10 |
| Character TTM | |
|---|---|
| Beta | 1.389 |
| Beta Downside | 1.663 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.56% |
| CAGR/Max DD | -0.05 |
EPS (Earnings per Share)
Revenue
Description: ULTA Ulta Beauty March 05, 2026
Ulta Beauty, Inc. (ULTA) is a specialty beauty retailer operating in the United States, Mexico, and Kuwait. The company sells branded and private label beauty products across multiple categories, including cosmetics, fragrance, and skincare. Its business model integrates retail stores, e-commerce platforms, and in-store beauty services. The beauty retail sector often sees strong customer loyalty programs and experiential retail elements.
Ulta Beauty distributes products through its physical stores, shop-in-shops, website, and mobile applications. The company also generates revenue from in-store services such as hair and makeup applications. The integration of product sales and services is a common strategy in the beauty industry to enhance customer engagement and average transaction value.
To deepen your understanding of ULTAs performance, consider exploring its detailed financial metrics on ValueRay.
Headlines to watch out for
- Consumer discretionary spending impacts beauty product sales
- E-commerce growth expands market reach and revenue
- Salon services drive in-store traffic and brand loyalty
- Private label product expansion boosts profit margins
- Supply chain disruptions increase operational costs
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 1.15b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -1.98 > 1.0 |
| NWC/Revenue: 7.42% < 20% (prev 11.06%; Δ -3.64% < -1%) |
| CFO/TA 0.22 > 3% & CFO 1.51b > Net Income 1.15b |
| Net Debt (1.76b) to EBITDA (1.84b): 0.95 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.0m) vs 12m ago -3.20% < -2% |
| Gross Margin: 39.10% > 18% (prev 0.39%; Δ 3.87k% > 0.5%) |
| Asset Turnover: 190.6% > 50% (prev 188.2%; Δ 2.44% > 0%) |
| Interest Coverage Ratio: 228.5 > 6 (EBITDA TTM 1.84b / Interest Expense TTM 6.75m) |
Altman Z'' 3.70
| A: 0.13 (Total Current Assets 3.14b - Total Current Liabilities 2.22b) / Total Assets 7.00b |
| B: 0.25 (Retained Earnings 1.74b / Total Assets 7.00b) |
| C: 0.24 (EBIT TTM 1.54b / Avg Total Assets 6.50b) |
| D: 0.41 (Book Value of Equity 1.74b / Total Liabilities 4.20b) |
| Altman-Z'' Score: 3.70 = AA |
Beneish M -0.94
| DSRI: 1.21 (Receivables 296.2m/223.3m, Revenue 12.39b/11.30b) |
| GMI: 0.99 (GM 39.10% / 38.84%) |
| AQI: 4.21 (AQ_t 0.09 / AQ_t-1 0.02) |
| SGI: 1.10 (Revenue 12.39b / 11.30b) |
| TATA: -0.05 (NI 1.15b - CFO 1.51b) / TA 7.00b) |
| Beneish M-Score: -0.94 (Cap -4..+1) = D |
What is the price of ULTA shares?
As of March 29, 2026, the stock is trading at USD 510.34 with a total of 622,212 shares traded.
Over the past week, the price has changed by -3.70%, over one month by -25.47%, over three months by -15.60% and over the past year by +37.80%.
Over the past week, the price has changed by -3.70%, over one month by -25.47%, over three months by -15.60% and over the past year by +37.80%.
Is ULTA a buy, sell or hold?
Ulta Beauty has received a consensus analysts rating of 3.68.
Therefor, it is recommend to hold ULTA.
- StrongBuy: 9
- Buy: 4
- Hold: 13
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ULTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 681.2 | 33.5% |
| Analysts Target Price | 681.2 | 33.5% |
ULTA Fundamental Data Overview March 28, 2026
P/E Trailing = 20.3289
P/E Forward = 18.6916
P/S = 1.8873
P/B = 8.3257
P/EG = 2.2211
Revenue TTM = 12.39b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.84b USD
Long Term Debt = 1.81b USD (estimated: total debt 2.18b - short term 369.0m)
Short Term Debt = 369.0m USD (from shortTermDebt, last quarter)
Debt = 2.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.76b USD (from netDebt column, last quarter)
Enterprise Value = 25.08b USD (23.39b + Debt 2.18b - CCE 494.2m)
Interest Coverage Ratio = 228.5 (Ebit TTM 1.54b / Interest Expense TTM 6.75m)
EV/FCF = 25.44x (Enterprise Value 25.08b / FCF TTM 985.6m)
FCF Yield = 3.93% (FCF TTM 985.6m / Enterprise Value 25.08b)
FCF Margin = 7.95% (FCF TTM 985.6m / Revenue TTM 12.39b)
Net Margin = 9.31% (Net Income TTM 1.15b / Revenue TTM 12.39b)
Gross Margin = 39.10% ((Revenue TTM 12.39b - Cost of Revenue TTM 7.55b) / Revenue TTM)
Gross Margin QoQ = 38.06% (prev 40.44%)
Tobins Q-Ratio = 3.58 (Enterprise Value 25.08b / Total Assets 7.00b)
Interest Expense / Debt = 0.12% (Interest Expense 2.62m / Debt 2.18b)
Taxrate = 24.45% (116.0m / 474.3m)
NOPAT = 1.16b (EBIT 1.54b * (1 - 24.45%))
Current Ratio = 1.41 (Total Current Assets 3.14b / Total Current Liabilities 2.22b)
Debt / Equity = 0.78 (Debt 2.18b / totalStockholderEquity, last quarter 2.80b)
Debt / EBITDA = 0.95 (Net Debt 1.76b / EBITDA 1.84b)
Debt / FCF = 1.78 (Net Debt 1.76b / FCF TTM 985.6m)
Total Stockholder Equity = 2.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.74% (Net Income 1.15b / Total Assets 7.00b)
RoE = 44.07% (Net Income TTM 1.15b / Total Stockholder Equity 2.62b)
RoCE = 34.79% (EBIT 1.54b / Capital Employed (Equity 2.62b + L.T.Debt 1.81b))
RoIC = 41.06% (NOPAT 1.16b / Invested Capital 2.84b)
WACC = 9.95% (E(23.39b)/V(25.57b) * Re(10.87%) + D(2.18b)/V(25.57b) * Rd(0.12%) * (1-Tc(0.24)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.26%
[DCF] Terminal Value 71.91% ; FCFF base≈977.0m ; Y1≈992.9m ; Y5≈1.09b
[DCF] Fair Price = 274.9 (EV 13.95b - Net Debt 1.76b = Equity 12.20b / Shares 44.4m; r=9.95% [WACC]; 5y FCF grow 1.36% → 3.0% )
EPS Correlation: 13.75 | EPS CAGR: 6.61% | SUE: -0.07 | # QB: 0
Revenue Correlation: 57.26 | Revenue CAGR: 14.50% | SUE: 1.11 | # QB: 4
EPS next Quarter (2026-04-30): EPS=6.94 | Chg7d=-0.293 | Chg30d=-0.302 | Revisions Net=-12 | Analysts=17
EPS current Year (2027-01-31): EPS=28.50 | Chg7d=+0.021 | Chg30d=+0.012 | Revisions Net=+2 | Growth EPS=+11.2% | Growth Revenue=+6.7%
EPS next Year (2028-01-31): EPS=31.52 | Chg7d=+0.051 | Chg30d=+0.216 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -0.86 (1 Up / 13 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.0% (Discount Rate 10.9% - Earnings Yield 4.9%)
[Growth] Growth Spread = +3.1% (Analyst 9.1% - Implied 6.0%)
P/E Forward = 18.6916
P/S = 1.8873
P/B = 8.3257
P/EG = 2.2211
Revenue TTM = 12.39b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.84b USD
Long Term Debt = 1.81b USD (estimated: total debt 2.18b - short term 369.0m)
Short Term Debt = 369.0m USD (from shortTermDebt, last quarter)
Debt = 2.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.76b USD (from netDebt column, last quarter)
Enterprise Value = 25.08b USD (23.39b + Debt 2.18b - CCE 494.2m)
Interest Coverage Ratio = 228.5 (Ebit TTM 1.54b / Interest Expense TTM 6.75m)
EV/FCF = 25.44x (Enterprise Value 25.08b / FCF TTM 985.6m)
FCF Yield = 3.93% (FCF TTM 985.6m / Enterprise Value 25.08b)
FCF Margin = 7.95% (FCF TTM 985.6m / Revenue TTM 12.39b)
Net Margin = 9.31% (Net Income TTM 1.15b / Revenue TTM 12.39b)
Gross Margin = 39.10% ((Revenue TTM 12.39b - Cost of Revenue TTM 7.55b) / Revenue TTM)
Gross Margin QoQ = 38.06% (prev 40.44%)
Tobins Q-Ratio = 3.58 (Enterprise Value 25.08b / Total Assets 7.00b)
Interest Expense / Debt = 0.12% (Interest Expense 2.62m / Debt 2.18b)
Taxrate = 24.45% (116.0m / 474.3m)
NOPAT = 1.16b (EBIT 1.54b * (1 - 24.45%))
Current Ratio = 1.41 (Total Current Assets 3.14b / Total Current Liabilities 2.22b)
Debt / Equity = 0.78 (Debt 2.18b / totalStockholderEquity, last quarter 2.80b)
Debt / EBITDA = 0.95 (Net Debt 1.76b / EBITDA 1.84b)
Debt / FCF = 1.78 (Net Debt 1.76b / FCF TTM 985.6m)
Total Stockholder Equity = 2.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.74% (Net Income 1.15b / Total Assets 7.00b)
RoE = 44.07% (Net Income TTM 1.15b / Total Stockholder Equity 2.62b)
RoCE = 34.79% (EBIT 1.54b / Capital Employed (Equity 2.62b + L.T.Debt 1.81b))
RoIC = 41.06% (NOPAT 1.16b / Invested Capital 2.84b)
WACC = 9.95% (E(23.39b)/V(25.57b) * Re(10.87%) + D(2.18b)/V(25.57b) * Rd(0.12%) * (1-Tc(0.24)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.26%
[DCF] Terminal Value 71.91% ; FCFF base≈977.0m ; Y1≈992.9m ; Y5≈1.09b
[DCF] Fair Price = 274.9 (EV 13.95b - Net Debt 1.76b = Equity 12.20b / Shares 44.4m; r=9.95% [WACC]; 5y FCF grow 1.36% → 3.0% )
EPS Correlation: 13.75 | EPS CAGR: 6.61% | SUE: -0.07 | # QB: 0
Revenue Correlation: 57.26 | Revenue CAGR: 14.50% | SUE: 1.11 | # QB: 4
EPS next Quarter (2026-04-30): EPS=6.94 | Chg7d=-0.293 | Chg30d=-0.302 | Revisions Net=-12 | Analysts=17
EPS current Year (2027-01-31): EPS=28.50 | Chg7d=+0.021 | Chg30d=+0.012 | Revisions Net=+2 | Growth EPS=+11.2% | Growth Revenue=+6.7%
EPS next Year (2028-01-31): EPS=31.52 | Chg7d=+0.051 | Chg30d=+0.216 | Revisions Net=-1 | Growth EPS=+10.6% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -0.86 (1 Up / 13 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.0% (Discount Rate 10.9% - Earnings Yield 4.9%)
[Growth] Growth Spread = +3.1% (Analyst 9.1% - Implied 6.0%)